1. Home
  2. DDOG vs ALNY Comparison

DDOG vs ALNY Comparison

Compare DDOG & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Datadog Inc.

DDOG

Datadog Inc.

HOLD

Current Price

$142.08

Market Cap

55.5B

Sector

Technology

ML Signal

HOLD

Logo Alnylam Pharmaceuticals Inc.

ALNY

Alnylam Pharmaceuticals Inc.

N/A

Current Price

$407.78

Market Cap

60.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DDOG
ALNY
Founded
2010
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
55.5B
60.1B
IPO Year
2019
2004

Fundamental Metrics

Financial Performance
Metric
DDOG
ALNY
Price
$142.08
$407.78
Analyst Decision
Buy
Strong Buy
Analyst Count
33
28
Target Price
$192.06
$479.45
AVG Volume (30 Days)
4.1M
1.8M
Earning Date
11-06-2025
10-30-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.31
0.33
Revenue
$3,211,691,000.00
$3,210,070,000.00
Revenue This Year
$28.86
$69.60
Revenue Next Year
$20.99
$42.67
P/E Ratio
$453.11
$1,213.35
Revenue Growth
26.63
53.24
52 Week Low
$81.63
$205.87
52 Week High
$201.69
$495.55

Technical Indicators

Market Signals
Indicator
DDOG
ALNY
Relative Strength Index (RSI) 35.18 41.05
Support Level $136.37 $388.54
Resistance Level $141.57 $479.79
Average True Range (ATR) 3.63 15.52
MACD -1.07 -2.20
Stochastic Oscillator 26.92 22.09

Price Performance

Historical Comparison
DDOG
ALNY

About DDOG Datadog Inc.

Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered via software as a service, enables clients to monitor and analyze their entire information technology infrastructure, from servers to applications and Python scripts. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of applications throughout their businesses to ensure uptime and latency objectives.

About ALNY Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Share on Social Networks: